Abstract
Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale–Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype interaction for both YBOCS total scores and compulsion scores was found
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pauls DL, Alsobrook JP 2nd, Goodman W, Rasmussen S, Leckman JF . A family study of obsessive-compulsive disorder Am J Psychiatry 1995 152: 76–84
Nestadt G, Samuels J, Riddle M, Bienvenu OJ 3rd, Liang KY, LaBuda M et al . A family study of obsessive-compulsive disorder Arch Gen Psychiatry 2000 57: 358–363
McGuffin P, Mawson D . Obsessive-compulsive neurosis: two identical twin pairs Br J Psychiatry 1980 137: 285–287
Cavallini MC, Pasquale L, Bellodi L, Smeraldi E . Complex segregation analysis for obsessive compulsive disorder and related disorders Am J Med Genet 1999 88: 38–43
Alsobrook JP II, Leckman JF, Goodman WK, Rasmussen SA, Pauls DL . Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores Am J Med Genet 1999 88: 669–675
Nestadt G, Lan T, Samuels J, Riddle M, Bienvenu OJ 3rd, Liang KY et al . Complex segregation analysis provides compelling evidence for a major gene underlying obsessive-compulsive disorder and for heterogeneity by sex Am J Hum Genet 2000 67: 1611–1616
Altemus M, Murphy DL, Greenberg B, Lesch KP . Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder Am J Med Genet 1996 67: 409–411
Cavallini MC, Di Bella D, Pasquale L, Henin M, Bellodi L . 5HT2C CYS23/SER23 polymorphism is not associated with obsessive-compulsive disorder Psychiatry Res 1998 77: 97–104
Billett EA, Richter MA, King N, Heils A, Lesch KP, Kennedy JL . Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene Mol Psychiatry 1997 2: 403–406
McDougle CJ, Epperson CN, Price LH, Gelernter J . Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder Mol Psychiatry 1998 3: 270–273
Bengel D, Greenberg BD, Cora-Locatelli G, Altemus M, Heils A, Li Q, Murphy DL . Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder Mol Psychiatry 1999 4: 463–466
Kinnear CJ, Niehaus DJ, Moolman-Smook JC, du Toit PL, van Kradenberg J, Weyers JB et al . Obsessive-compulsive disorder and the promoter region polymorphism (5-HTTLPR) in the serotonin transporter gene (SLC6A4): a negative association study in the Afrikaner population Int J Neuropsychopharmacol 2000 3: 327–331
Baron M . The search for complex disease genes: fault by linkage or fault by association? Mol Psychiatry 2001 6: 143–149
Sasson Y, Amiatz R, Chopra M, Nakash N, Zohar J . Treatment approaches to OCD—the role of serotonin. In: Bellodi L, Cavallaro R (eds) The Basal-cortical Function in Obsessive Compulsive Disorder Spectrum Pacini Editore: Pisa 2000 213–230
Goodman WK, McDougle CJ, Price LH . Pharmacotherapy of obsessive compulsive disorder J Clin Psychiatry 1992 53 Suppl: 29–37
Pigott TA, Seay SM . A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder J Clin Psychiatry 1999 60: 101–106
Hollander E, Kaplan A, Allen A, Cartwright C . Pharmacotherapy for obsessive-compulsive disorder Psychiatr Clin North Am 2000 23: 643–656
Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP . Allelic variation of human serotonin transporter gene expression J Neurochem 1996 66: 2621–2624
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al . Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 1996 274: 1527–1531
Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al . Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression Neuropsychopharmacology 2000 23: 587–590
Smeraldi S, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M . Polymorphism within the promoter of the serotonin transporter and antidepressant efficacy of fluvoxamine Mol Psychiatry 1998 3: 508–511
Zanardi R, Benedetti F, Catalano M, Di Bella D, Smeraldi E . Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene Psychopharmacology 2000 20: 105–107
Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ . Serotonin transporter gene polymorphism and antidepressant response Neuroreport 2000 11: 215–219
McDougle CJ, Goodman WK, Price LH . The pharmacotherapy of obsessive-compulsive disorder Pharmacopsychiatry 1993 26 Suppl 1: 24–29
Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L . Clinical predictors of drug response in obsessive-compulsive disorder J Clin Psychopharmacol 2000 21: 488–492
Catalano M . The challenges of psychopharmacogenetics Am J Hum Genet 1999 65: 606–610
Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E . Serotonin transporter gene associated with lithium prophylaxis in mood disorders The Pharmacogenomics J 2001 1: 71–77
McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH . A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder Arch Gen Psychiatry 2000 57: 794–801
Locatelli M, Moresco RM, Perani D, Henin M, Gobbo C, Bellodi L . Brain imaging in obsessive-compulsive disorder: a review of the past and challenge for the future. In: Bellodi L, Cavallaro R (eds) The Basal-cortical Function in Obsessive Compulsive Disorder Spectrum Pacini Editore: Pisa 2000 49–80
Montgomery SA . Pharmachological treatment of obsessive-compulsive disorder. In: Hollander E, Zohar J, Marazziti D, Olivier B (eds) Current Insights in Obsessive Disorder Wiley: New York 1994 215–226
Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ et al . A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder Arch Gen Psychiatry 1994 51: 559–567
Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L et al . Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder Arch Gen Psychiatry 1995 52: 289–295
Blier P, de Montigny C . Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses Biol Psychiatry 1998 44: 313–323
American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders APA: Washington DC 1994
Robins LN, Helzer JE, Cottler L . NIMH Diagnostic Interview Schedule. Version III-R (DIS-R) Washington University School of Medicine: St Louis, MO 1989
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleishmann RL, Hill CL et al . The Yale-Brown Obsessive Compulsive Scale, I: development, use and reliability Arch Gen Psychiatry 1989 46: 1006–1011
Andreasen NC, Endicott JR, Winokour J . The family history method using diagnostic criteria: reliability and validity Arch Gen Psychiatry 1977 34: 1229–1235
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH . Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics Arch Gen Psychiatry 1994 51: 302–308
Mundo E, Bianchi L, Bellodi L . Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study J Clin Psychopharmacol 1997 17: 1–5
Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi . Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor Neuropsychobiology 1994 29: 108–111
Deckert J, Catalano M, Heils A, Di Bella D, Friess F, Politi E et al . Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder Psychiatr Genet 1997 7: 45–47
Statsoft Inc. Statistica, 1984–2000
Acknowledgements
This work was partly supported by GRANT E529 from Telethon Foundation Onlus.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Di Bella, D., Erzegovesi, S., Cavallini, M. et al. Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J 2, 176–181 (2002). https://doi.org/10.1038/sj.tpj.6500090
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500090
Keywords
This article is cited by
-
Whole-genome association analysis of treatment response in obsessive-compulsive disorder
Molecular Psychiatry (2016)
-
Is serotonin transporter polymorphism (5-HTTLPR) allele status a predictor for obsessive-compulsive disorder? A meta-analysis
Archives of Women's Mental Health (2015)
-
The genomics of selection in dogs and the parallel evolution between dogs and humans
Nature Communications (2013)
-
Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive–compulsive disorder
The Pharmacogenomics Journal (2013)
-
Association of SLC6A4 variants with obsessive-compulsive disorder in a large multicenter US family study
Molecular Psychiatry (2011)